The world's first tumor targeting IL-15 successfully administered in the United States for the first time

On December 9, 2019, Boji biomedical technology (Hangzhou) Co., Ltd., a new and cutting-edge biotechnology company committed to innovative drug research and development in Hangzhou, announced that the world's first tumor targeting IL-15 fusion protein (bj-001), which is independently developed by Boji and has global patents, was next in San Antonio, Texas, USA on December 4, 2019 Oncology Clinical Center successfully completed the first drug administration for the first patient At present, all patients are normal Bj-001 bj-001 is the world's first tumor targeting IL-15 fusion protein independently developed by Biologie and has global intellectual property rights Its domain contains targeted α V β 3, α V β 5 and / or The target molecules of tumor cells with high expression of integrin, such as α V β 6, whose IL-15 structure can be combined with the IL-2 / 15R β γ C receptor complex expressed on immune cells (especially NK and T cells) to activate the immune system and kill tumor This design of bj-001 endows it with the ability of seed aggregation in tumor microenvironment, so that it has the potential to reduce systemic toxicity and enhance the efficacy In addition, the effect of IL-15 on lymphocyte proliferation in tumor area also has the potential to transform the cold tumor which has no response to the commonly used immunosuppressants such as anti-PD-1 antibody into the hot tumor which has response, which will greatly improve the efficiency of existing tumor immunotherapy drugs and benefit more patients Therefore, the tumor targeting IL-15 of Boji biomedicine is expected to become another new star in tumor immunotherapy, with great social and market potential, benefiting patients all over the world About interdisciplinary biology Boji biology is a biotechnology company dedicated to the research and development of innovative drugs It is founded by overseas experts with many years of experience in the research and development of innovative drugs, including experts in the major special review of national "major new drug creation" science and technology It has an antibody discovery platform protected by trade secrets and top technologies at home and abroad Currently, it is mainly used in the research and development of tumor and infectious diseases Medicine The company's main research and management team has many years of experience in research and development of antibody drugs in domestic and foreign research and development companies and national key research institutions, especially in European and American multinational companies Focusing on the global view of R & D and based on abundant capital support, Boyi biology has made a global layout of R & D from a global perspective since its inception At the same time, it has two major R & D laboratories in San Francisco, USA and Hangzhou, China, which enable the company to realize a comprehensive collection of talents, technology, management and capital market in the early stage of entrepreneurship, laying a solid foundation for the company's global positioning and development The foundation of reality Established only 2 years ago, it has become China's cutting-edge biotechnology company Adorable adorable